世界の増殖性糖尿病性網膜症市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Proliferative Diabetic Retinopathy Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12617 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、増殖性糖尿病性網膜症のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。増殖性糖尿病性網膜症の種類別市場規模（抗VEGF剤、コルチコステロイド）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・増殖性糖尿病性網膜症の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Intas Pharmaceuticals、Santen Pharmaceutical、Bausch Health、Allergan Plc、Regeneron Pharmaceuticals、Merck KGaA、Cipla、Genentech, Inc. (Roche Holdings)、Novartis、Pfizer ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：抗VEGF剤、コルチコステロイド ・用途別分析2016年-2026年：病院、クリニック、その他 ・増殖性糖尿病性網膜症の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・増殖性糖尿病性網膜症のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・増殖性糖尿病性網膜症のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・増殖性糖尿病性網膜症の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・増殖性糖尿病性網膜症の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Proliferative Diabetic Retinopathy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Proliferative Diabetic Retinopathy size is estimated to be USD 556.3 million in 2026 from USD 454.7 million in 2020, with a change XX% between 2020 and 2021. The global Proliferative Diabetic Retinopathy market size is expected to grow at a CAGR of 5.2% for the next five years.

Market segmentation
Proliferative Diabetic Retinopathy market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Anti-VEGF Agents
Corticosteroids

Market segment by Application, can be divided into
Hospitals
Clinics
Others

Market segment by players, this report covers
Intas Pharmaceuticals
Santen Pharmaceutical
Bausch Health
Allergan Plc
Regeneron Pharmaceuticals
Merck KGaA
Cipla
Genentech, Inc. (Roche Holdings)
Novartis
Pfizer

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Proliferative Diabetic Retinopathy product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Proliferative Diabetic Retinopathy, with revenue, gross margin and global market share of Proliferative Diabetic Retinopathy from 2019 to 2021.
Chapter 3, the Proliferative Diabetic Retinopathy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Proliferative Diabetic Retinopathy market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Proliferative Diabetic Retinopathy research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Proliferative Diabetic Retinopathy
1.2 Classification of Proliferative Diabetic Retinopathy by Type
1.2.1 Overview: Global Proliferative Diabetic Retinopathy Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Proliferative Diabetic Retinopathy Revenue Market Share by Type in 2020
1.2.3 Anti-VEGF Agents
1.2.4 Corticosteroids
1.3 Global Proliferative Diabetic Retinopathy Market by Application
1.3.1 Overview: Global Proliferative Diabetic Retinopathy Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Proliferative Diabetic Retinopathy Market Size & Forecast
1.5 Global Proliferative Diabetic Retinopathy Market Size and Forecast by Region
1.5.1 Global Proliferative Diabetic Retinopathy Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Proliferative Diabetic Retinopathy Market Size by Region, (2016-2021)
1.5.3 North America Proliferative Diabetic Retinopathy Market Size and Prospect (2016-2026)
1.5.4 Europe Proliferative Diabetic Retinopathy Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Proliferative Diabetic Retinopathy Market Size and Prospect (2016-2026)
1.5.6 South America Proliferative Diabetic Retinopathy Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Proliferative Diabetic Retinopathy Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Proliferative Diabetic Retinopathy Market Drivers
1.6.2 Proliferative Diabetic Retinopathy Market Restraints
1.6.3 Proliferative Diabetic Retinopathy Trends Analysis
2 Company Profiles
2.1 Intas Pharmaceuticals
2.1.1 Intas Pharmaceuticals Details
2.1.2 Intas Pharmaceuticals Major Business
2.1.3 Intas Pharmaceuticals Proliferative Diabetic Retinopathy Product and Solutions
2.1.4 Intas Pharmaceuticals Proliferative Diabetic Retinopathy Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Intas Pharmaceuticals Recent Developments and Future Plans
2.2 Santen Pharmaceutical
2.2.1 Santen Pharmaceutical Details
2.2.2 Santen Pharmaceutical Major Business
2.2.3 Santen Pharmaceutical Proliferative Diabetic Retinopathy Product and Solutions
2.2.4 Santen Pharmaceutical Proliferative Diabetic Retinopathy Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Santen Pharmaceutical Recent Developments and Future Plans
2.3 Bausch Health
2.3.1 Bausch Health Details
2.3.2 Bausch Health Major Business
2.3.3 Bausch Health Proliferative Diabetic Retinopathy Product and Solutions
2.3.4 Bausch Health Proliferative Diabetic Retinopathy Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Bausch Health Recent Developments and Future Plans
2.4 Allergan Plc
2.4.1 Allergan Plc Details
2.4.2 Allergan Plc Major Business
2.4.3 Allergan Plc Proliferative Diabetic Retinopathy Product and Solutions
2.4.4 Allergan Plc Proliferative Diabetic Retinopathy Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Allergan Plc Recent Developments and Future Plans
2.5 Regeneron Pharmaceuticals
2.5.1 Regeneron Pharmaceuticals Details
2.5.2 Regeneron Pharmaceuticals Major Business
2.5.3 Regeneron Pharmaceuticals Proliferative Diabetic Retinopathy Product and Solutions
2.5.4 Regeneron Pharmaceuticals Proliferative Diabetic Retinopathy Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Regeneron Pharmaceuticals Recent Developments and Future Plans
2.6 Merck KGaA
2.6.1 Merck KGaA Details
2.6.2 Merck KGaA Major Business
2.6.3 Merck KGaA Proliferative Diabetic Retinopathy Product and Solutions
2.6.4 Merck KGaA Proliferative Diabetic Retinopathy Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Merck KGaA Recent Developments and Future Plans
2.7 Cipla
2.7.1 Cipla Details
2.7.2 Cipla Major Business
2.7.3 Cipla Proliferative Diabetic Retinopathy Product and Solutions
2.7.4 Cipla Proliferative Diabetic Retinopathy Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Cipla Recent Developments and Future Plans
2.8 Genentech, Inc. (Roche Holdings)
2.8.1 Genentech, Inc. (Roche Holdings) Details
2.8.2 Genentech, Inc. (Roche Holdings) Major Business
2.8.3 Genentech, Inc. (Roche Holdings) Proliferative Diabetic Retinopathy Product and Solutions
2.8.4 Genentech, Inc. (Roche Holdings) Proliferative Diabetic Retinopathy Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Genentech, Inc. (Roche Holdings) Recent Developments and Future Plans
2.9 Novartis
2.9.1 Novartis Details
2.9.2 Novartis Major Business
2.9.3 Novartis Proliferative Diabetic Retinopathy Product and Solutions
2.9.4 Novartis Proliferative Diabetic Retinopathy Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Novartis Recent Developments and Future Plans
2.10 Pfizer
2.10.1 Pfizer Details
2.10.2 Pfizer Major Business
2.10.3 Pfizer Proliferative Diabetic Retinopathy Product and Solutions
2.10.4 Pfizer Proliferative Diabetic Retinopathy Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Pfizer Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Proliferative Diabetic Retinopathy Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Proliferative Diabetic Retinopathy Players Market Share
3.2.2 Top 10 Proliferative Diabetic Retinopathy Players Market Share
3.2.3 Market Competition Trend
3.3 Proliferative Diabetic Retinopathy Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Proliferative Diabetic Retinopathy Revenue and Market Share by Type (2016-2021)
4.2 Global Proliferative Diabetic Retinopathy Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Proliferative Diabetic Retinopathy Revenue Market Share by Application (2016-2021)
5.2 Proliferative Diabetic Retinopathy Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Proliferative Diabetic Retinopathy Revenue by Type (2016-2026)
6.2 North America Proliferative Diabetic Retinopathy Revenue by Application (2016-2026)
6.3 North America Proliferative Diabetic Retinopathy Market Size by Country
6.3.1 North America Proliferative Diabetic Retinopathy Revenue by Country (2016-2026)
6.3.2 United States Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
6.3.3 Canada Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
6.3.4 Mexico Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Proliferative Diabetic Retinopathy Revenue by Type (2016-2026)
7.2 Europe Proliferative Diabetic Retinopathy Revenue by Application (2016-2026)
7.3 Europe Proliferative Diabetic Retinopathy Market Size by Country
7.3.1 Europe Proliferative Diabetic Retinopathy Revenue by Country (2016-2026)
7.3.2 Germany Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
7.3.3 France Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
7.3.5 Russia Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
7.3.6 Italy Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Proliferative Diabetic Retinopathy Revenue by Type (2016-2026)
8.2 Asia-Pacific Proliferative Diabetic Retinopathy Revenue by Application (2016-2026)
8.3 Asia-Pacific Proliferative Diabetic Retinopathy Market Size by Region
8.3.1 Asia-Pacific Proliferative Diabetic Retinopathy Revenue by Region (2016-2026)
8.3.2 China Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
8.3.3 Japan Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
8.3.4 South Korea Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
8.3.5 India Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
8.3.7 Australia Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Proliferative Diabetic Retinopathy Revenue by Type (2016-2026)
9.2 South America Proliferative Diabetic Retinopathy Revenue by Application (2016-2026)
9.3 South America Proliferative Diabetic Retinopathy Market Size by Country
9.3.1 South America Proliferative Diabetic Retinopathy Revenue by Country (2016-2026)
9.3.2 Brazil Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
9.3.3 Argentina Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Proliferative Diabetic Retinopathy Revenue by Type (2016-2026)
10.2 Middle East & Africa Proliferative Diabetic Retinopathy Revenue by Application (2016-2026)
10.3 Middle East & Africa Proliferative Diabetic Retinopathy Market Size by Country
10.3.1 Middle East & Africa Proliferative Diabetic Retinopathy Revenue by Country (2016-2026)
10.3.2 Turkey Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
10.3.4 UAE Proliferative Diabetic Retinopathy Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Proliferative Diabetic Retinopathy Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Proliferative Diabetic Retinopathy Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Proliferative Diabetic Retinopathy Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Proliferative Diabetic Retinopathy Revenue (USD Million) by Region (2016-2021)
Table 5. Global Proliferative Diabetic Retinopathy Revenue Market Share by Region (2021-2026)
Table 6. Intas Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 7. Intas Pharmaceuticals Major Business
Table 8. Intas Pharmaceuticals Proliferative Diabetic Retinopathy Product and Solutions
Table 9. Intas Pharmaceuticals Proliferative Diabetic Retinopathy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Santen Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 11. Santen Pharmaceutical Major Business
Table 12. Santen Pharmaceutical Proliferative Diabetic Retinopathy Product and Solutions
Table 13. Santen Pharmaceutical Proliferative Diabetic Retinopathy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Bausch Health Corporate Information, Head Office, and Major Competitors
Table 15. Bausch Health Major Business
Table 16. Bausch Health Proliferative Diabetic Retinopathy Product and Solutions
Table 17. Bausch Health Proliferative Diabetic Retinopathy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Allergan Plc Corporate Information, Head Office, and Major Competitors
Table 19. Allergan Plc Major Business
Table 20. Allergan Plc Proliferative Diabetic Retinopathy Product and Solutions
Table 21. Allergan Plc Proliferative Diabetic Retinopathy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Regeneron Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 23. Regeneron Pharmaceuticals Major Business
Table 24. Regeneron Pharmaceuticals Proliferative Diabetic Retinopathy Product and Solutions
Table 25. Regeneron Pharmaceuticals Proliferative Diabetic Retinopathy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Merck KGaA Corporate Information, Head Office, and Major Competitors
Table 27. Merck KGaA Major Business
Table 28. Merck KGaA Proliferative Diabetic Retinopathy Product and Solutions
Table 29. Merck KGaA Proliferative Diabetic Retinopathy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Cipla Corporate Information, Head Office, and Major Competitors
Table 31. Cipla Major Business
Table 32. Cipla Proliferative Diabetic Retinopathy Product and Solutions
Table 33. Cipla Proliferative Diabetic Retinopathy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Genentech, Inc. (Roche Holdings) Corporate Information, Head Office, and Major Competitors
Table 35. Genentech, Inc. (Roche Holdings) Major Business
Table 36. Genentech, Inc. (Roche Holdings) Proliferative Diabetic Retinopathy Product and Solutions
Table 37. Genentech, Inc. (Roche Holdings) Proliferative Diabetic Retinopathy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Novartis Corporate Information, Head Office, and Major Competitors
Table 39. Novartis Major Business
Table 40. Novartis Proliferative Diabetic Retinopathy Product and Solutions
Table 41. Novartis Proliferative Diabetic Retinopathy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Pfizer Corporate Information, Head Office, and Major Competitors
Table 43. Pfizer Major Business
Table 44. Pfizer Proliferative Diabetic Retinopathy Product and Solutions
Table 45. Pfizer Proliferative Diabetic Retinopathy Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Proliferative Diabetic Retinopathy Revenue (USD Million) by Players (2019-2021)
Table 47. Global Proliferative Diabetic Retinopathy Revenue Share by Players (2019-2021)
Table 48. Breakdown of Proliferative Diabetic Retinopathy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Proliferative Diabetic Retinopathy Players Head Office, Products and Services Provided
Table 50. Proliferative Diabetic Retinopathy Mergers & Acquisitions in the Past Five Years
Table 51. Proliferative Diabetic Retinopathy New Entrants and Expansion Plans
Table 52. Global Proliferative Diabetic Retinopathy Revenue (USD Million) by Type (2016-2021)
Table 53. Global Proliferative Diabetic Retinopathy Revenue Share by Type (2016-2021)
Table 54. Global Proliferative Diabetic Retinopathy Revenue Forecast by Type (2021-2026)
Table 55. Global Proliferative Diabetic Retinopathy Revenue by Application (2016-2021)
Table 56. Global Proliferative Diabetic Retinopathy Revenue Forecast by Application (2021-2026)
Table 57. North America Proliferative Diabetic Retinopathy Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Proliferative Diabetic Retinopathy Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Proliferative Diabetic Retinopathy Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Proliferative Diabetic Retinopathy Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Proliferative Diabetic Retinopathy Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Proliferative Diabetic Retinopathy Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Proliferative Diabetic Retinopathy Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Proliferative Diabetic Retinopathy Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Proliferative Diabetic Retinopathy Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Proliferative Diabetic Retinopathy Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Proliferative Diabetic Retinopathy Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Proliferative Diabetic Retinopathy Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Proliferative Diabetic Retinopathy Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Proliferative Diabetic Retinopathy Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Proliferative Diabetic Retinopathy Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Proliferative Diabetic Retinopathy Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Proliferative Diabetic Retinopathy Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Proliferative Diabetic Retinopathy Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Proliferative Diabetic Retinopathy Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Proliferative Diabetic Retinopathy Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Proliferative Diabetic Retinopathy Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Proliferative Diabetic Retinopathy Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Proliferative Diabetic Retinopathy Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Proliferative Diabetic Retinopathy Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Proliferative Diabetic Retinopathy Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Proliferative Diabetic Retinopathy Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Proliferative Diabetic Retinopathy Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Proliferative Diabetic Retinopathy Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Proliferative Diabetic Retinopathy Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Proliferative Diabetic Retinopathy Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Proliferative Diabetic Retinopathy Picture
Figure 2. Global Proliferative Diabetic Retinopathy Revenue Market Share by Type in 2020
Figure 3. Anti-VEGF Agents
Figure 4. Corticosteroids
Figure 5. Proliferative Diabetic Retinopathy Revenue Market Share by Application in 2020
Figure 6. Hospitals Picture
Figure 7. Clinics Picture
Figure 8. Others Picture
Figure 9. Global Proliferative Diabetic Retinopathy Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Proliferative Diabetic Retinopathy Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Proliferative Diabetic Retinopathy Revenue Market Share by Region (2016-2026)
Figure 12. Global Proliferative Diabetic Retinopathy Revenue Market Share by Region in 2020
Figure 13. North America Proliferative Diabetic Retinopathy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Proliferative Diabetic Retinopathy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Proliferative Diabetic Retinopathy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Proliferative Diabetic Retinopathy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Middle East and Africa Proliferative Diabetic Retinopathy Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Proliferative Diabetic Retinopathy Market Drivers
Figure 19. Proliferative Diabetic Retinopathy Market Restraints
Figure 20. Proliferative Diabetic Retinopathy Market Trends
Figure 21. Intas Pharmaceuticals Recent Developments and Future Plans
Figure 22. Santen Pharmaceutical Recent Developments and Future Plans
Figure 23. Bausch Health Recent Developments and Future Plans
Figure 24. Allergan Plc Recent Developments and Future Plans
Figure 25. Regeneron Pharmaceuticals Recent Developments and Future Plans
Figure 26. Merck KGaA Recent Developments and Future Plans
Figure 27. Cipla Recent Developments and Future Plans
Figure 28. Genentech, Inc. (Roche Holdings) Recent Developments and Future Plans
Figure 29. Novartis Recent Developments and Future Plans
Figure 30. Pfizer Recent Developments and Future Plans
Figure 31. Global Proliferative Diabetic Retinopathy Revenue Share by Players in 2020
Figure 32. Proliferative Diabetic Retinopathy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 33. Global Top 3 Players Proliferative Diabetic Retinopathy Revenue Market Share in 2020
Figure 34. Global Top 10 Players Proliferative Diabetic Retinopathy Revenue Market Share in 2020
Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 36. Global Proliferative Diabetic Retinopathy Revenue Share by Type in 2020
Figure 37. Global Proliferative Diabetic Retinopathy Market Share Forecast by Type (2021-2026)
Figure 38. Global Proliferative Diabetic Retinopathy Revenue Share by Application in 2020
Figure 39. Global Proliferative Diabetic Retinopathy Market Share Forecast by Application (2021-2026)
Figure 40. North America Proliferative Diabetic Retinopathy Sales Market Share by Type (2016-2026)
Figure 41. North America Proliferative Diabetic Retinopathy Sales Market Share by Application (2016-2026)
Figure 42. North America Proliferative Diabetic Retinopathy Revenue Market Share by Country (2016-2026)
Figure 43. United States Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe Proliferative Diabetic Retinopathy Sales Market Share by Type (2016-2026)
Figure 47. Europe Proliferative Diabetic Retinopathy Sales Market Share by Application (2016-2026)
Figure 48. Europe Proliferative Diabetic Retinopathy Revenue Market Share by Country (2016-2026)
Figure 49. Germany Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. France Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. United Kingdom Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Russia Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Italy Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Asia-Pacific Proliferative Diabetic Retinopathy Sales Market Share by Type (2016-2026)
Figure 55. Asia-Pacific Proliferative Diabetic Retinopathy Sales Market Share by Application (2016-2026)
Figure 56. Asia-Pacific Proliferative Diabetic Retinopathy Revenue Market Share by Region (2016-2026)
Figure 57. China Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Japan Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. South Korea Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. India Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Southeast Asia Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Australia Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South America Proliferative Diabetic Retinopathy Sales Market Share by Type (2016-2026)
Figure 64. South America Proliferative Diabetic Retinopathy Sales Market Share by Application (2016-2026)
Figure 65. South America Proliferative Diabetic Retinopathy Revenue Market Share by Country (2016-2026)
Figure 66. Brazil Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Argentina Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Middle East and Africa Proliferative Diabetic Retinopathy Sales Market Share by Type (2016-2026)
Figure 69. Middle East and Africa Proliferative Diabetic Retinopathy Sales Market Share by Application (2016-2026)
Figure 70. Middle East and Africa Proliferative Diabetic Retinopathy Revenue Market Share by Country (2016-2026)
Figure 71. Turkey Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Saudi Arabia Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. UAE Proliferative Diabetic Retinopathy Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Methodology
Figure 75. Research Process and Data Source

---